The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Emollients and moisturisers for eczema
Open accessAbstract
BACKGROUND: Eczema is a chronic skin disease characterised by dry skin, intense itching, inflammatory skin lesions, and a considerable impact on quality of life. Moisturisation is an integral part of treatment, but it is unclear if moisturisers are effective. OBJECTIVES: To assess the effects of moisturisers for eczema. SEARCH METHODS: We searched the following databases to December 2015: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, the GREAT database. We searched five trials registers and checked references of included and excluded studies for further relevant trials. SELECTION CRITERIA: Randomised controlled trials in people with eczema. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. MAIN RESULTS: We included 77 studies (6603 participants, mean age: 18.6 years, mean duration: 6.7 weeks). We assessed 36 studies as at a high risk of bias, 34 at unclear risk, and seven at low risk. Twenty-four studies assessed our primary outcome 'participant-assessed disease severity', 13 assessed 'satisfaction', and 41 assessed 'adverse events'. Secondary outcomes included investigator-assessed disease severity (addressed in 65 studies), skin barrier function (29), flare prevention (16), quality of life (10), and corticosteroid use (eight). Adverse events reporting was limited (smarting, stinging, pruritus, erythema, folliculitis).Six studies evaluated moisturiser versus no moisturiser. 'Participant-assessed disease severity' and 'satisfaction' were not assessed. Moisturiser use yielded lower SCORAD than no moisturiser (three studies, 276 participants, mean difference (MD) -2.42, 95% confidence interval (CI) -4.55 to -0.28), but the minimal important difference (MID) (8.7) was unmet. There were fewer flares with moisturisers (two studies, 87 participants, RR 0.40, 95% CI 0.23 to 0.70), time to flare was prolonged (median: 180 versus 30 days), and less topical corticosteroids were needed (two studies, 222 participants, MD -9.30 g, 95% CI -15.3 to -3.27). There was no statistically significant difference in adverse events (one study, 173 participants, risk ratio (RR) 15.34, 95% CI 0.90 to 261.64). Evidence for these outcomes was low quality.With Atopiclair (three studies), 174/232 participants experienced improvement in participant-assessed disease severity versus 27/158 allocated to vehicle (RR 4.51, 95% CI 2.19 to 9.29). Atopiclair decreased itching (four studies, 396 participants, MD -2.65, 95% CI -4.21 to -1.09) and achieved more frequent satisfaction (two studies, 248 participants, RR 2.14, 95% CI 1.58 to 2.89), fewer flares (three studies, 397 participants, RR 0.18, 95% CI 0.11 to 0.31), and lower EASI (four studies, 426 participants, MD -4.0, 95% CI -5.42 to -2.57), but MID (6.6) was unmet. The number of participants reporting adverse events was not statistically different (four studies, 430 participants, RR 1.03, 95% CI 0.79 to 1.33). Evidence for these outcomes was moderate quality.Participants reported skin improvement more frequently with urea-containing cream than placebo (one study, 129 participants, RR 1.28, 95% CI 1.06 to 1.53; low-quality evidence), with equal satisfaction between the two groups (one study, 38 participants, low-quality evidence). Urea-containing cream improved dryness (investigator-assessed) more frequently (one study, 128 participants, RR 1.40, 95% CI 1.14 to 1.71; moderate-quality evidence) with fewer flares (one study, 44 participants, RR 0.47, 95% CI 0.24 to 0.92; low-quality evidence), but more participants in this group reported adverse events (one study, 129 participants, RR 1.65, 95% CI 1.16 to 2.34; moderate-quality evidence).Three studies assessed glycerol-containing moisturiser versus vehicle or placebo. More participants in the glycerol group noticed skin improvement (one study, 134 participants, RR 1.22, 95% CI 1.01 to 1.48; moderate-quality evidence), and this group saw improved investigator-assessed SCORAD (one study, 249 participants, MD -2.20, 95% CI -3.44 to -0.96; high-quality evidence), but MID was unmet. Participant satisfaction was not addressed. The number of participants reporting adverse events was not statistically significant (two studies, 385 participants, RR 0.90, 95% CI 0.68 to 1.19; moderate-quality evidence).Four studies investigated oat-containing moisturisers versus no treatment or vehicle. No significant differences between groups were reported for participant-assessed disease severity (one study, 50 participants, RR 1.11, 95% CI 0.84 to 1.46; low-quality evidence), satisfaction (one study, 50 participants, RR 1.06, 95% CI 0.74 to 1.52; very low-quality evidence), and investigator-assessed disease severity (three studies, 272 participants, standardised mean difference (SMD) -0.23, 95% CI -0.66 to 0.21; low-quality evidence). In the oat group, there were fewer flares (one study, 43 participants, RR 0.31, 95% CI 0.12 to 0.7; low-quality evidence) and less topical corticosteroids needed (two studies,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–211 of 211
Santer, M., Rumsby, K., Ridd, M. J., Francis, N. A., Stuart, B. L., Chorozoglou, M., Wood, W., Roberts, A., Thomas, K. S., Williams, H. C., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009575 · Cited by 12
Allergic characteristics of urban schoolchildren with atopic eczema in Ghana
Hogewoning, A. A., Larbi, I. A., Addo, H. A., Amoah, A. S., Boakye, D. A., Hartgers, F. C., Yazdanbakhsh, M., van Ree, R., Bavinck, J. B., & Lavrijsen, A. P. M. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03655.x · Cited by 11
Self-citationPoint and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda
Hogewoning, A. A., Bavinck, J. N. B., Amoah, A. S., et al. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04106.x · Cited by 10
Boyle, R. J., Bath-Hextall, F. J., Donath, S. M., Murrell, D. F., Tang, M., Taylor, J., & Varigos, G. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006135 · Cited by 10
Bohnsack, K., Tausch, I., Gassmüller, J., et al. (1997) · H&G Zeitschrift für Hautkrankheiten · Cited by 8
A daily oat-based skin care regimen for atopic skin
(2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.306 · Cited by 7
Complementary and alternative medicine treatments for atopic eczema
Jadotte, Y. T., Santer, M., Vakirlis, E., Schwartz, R. A., Bauer, A., Gundersen, D. A., Mossman, K., & Lewith, G. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010938.pub2 · Cited by 6
Specific allergen immunotherapy for the treatment of atopic eczema
Calderón, M. A., Boyle, R. J., Nankervis, H., Núñez, I. G., Williams, H. C., & Durham, S. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008774 · Cited by 6
Interventions to reduce Staphylococcus aureus for atopic eczema
Ravenscroft, J., Williams, H. C., Weston, V., Page, J., & Williams, R. E. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003871 · Cited by 4
Faergemann, J., Olsson, P., & Svensson, �. (2009) · Acta Dermato Venereologica · doi:10.2340/00015555-0567 · Cited by 4
Different strategies for using topical corticosteroids for established eczema
Moed, H. D., Yang, Q., Oranje, A. P., Panda, S., & van der Wouden, J. C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010080.pub2 · Cited by 3
Cited by
Chu, D. K., Schneider, L., Asiniwasis, R. N., Boguniewicz, M., De Benedetto, A., Ellison, K., Frazier, W. T., Greenhawt, M., Huynh, J., Kim, E., et al. (2024) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.11.009 · Cited by 380
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
Chalmers, J. R., Haines, R. H., Bradshaw, L. E., Montgomery, A. A., Thomas, K. S., Brown, S. J., Ridd, M. J., Lawton, S., Simpson, E. L., Cork, M. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32984-8 · Cited by 317
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18429 · Cited by 289
Self-citationGuidelines for diagnosis, prevention, and treatment of hand eczema
Thyssen, J. P., Schuttelaar, M. L. A., Alfonso, J. H., Andersen, K. E., Angelova‐Fischer, I., Arents, B. W. M., Bauer, A., Brans, R., Cannavo, A., Christoffers, W. A., et al. (2022) · Contact Dermatitis · doi:10.1111/cod.14035 · Cited by 282
Self-citationXu, S., Kwa, M., Lohman, M. E., Evers-Meltzer, R., & Silverberg, J. I. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.3046 · Cited by 90
Metadata
- Authors
- van Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A. P., & Arents, B. W.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-02-06
- Volume
- 2020
- Issue
- 8
- Pages
- CD012119-CD012119
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2296429471
- Cited by
- 260
- References
- 211
- FWCI
- 26.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.